Literature DB >> 22001920

The serine protease HtrA2 cleaves UCH-L1 and inhibits its hydrolase activity: implication in the UCH-L1-mediated cell death.

Dae-Wook Park1, Min-Kyung Nam, Hyangshuk Rhim.   

Abstract

Ubiquitin (Ub) carboxyl-terminal hydrolase L1 (UCH-L1) has dual functions, such as hydrolase activity on the chemical bonds formed by the C-terminal Gly of Ub and dimerization-dependent ubiquitin ligase activity. Accumulating evidence suggests that dual activities of UCH-L1 were intimately associated with Parkinson's diseases (PD) and cancer. However, the molecular mechanism that regulates UCH-L1 enzymatic activity has not yet been fully elucidated. The serine protease high temperature requirement A2 (HtrA2), a PD-associated gene, is important in regulating cell survival as well as apoptosis. Using in vitro and in vivo cleavage assays, we have demonstrated that UCH-L1 is a natural substrate for the serine protease HtrA2 in the apoptotic pathway. Notably, we show that released, cytosolic HtrA2 decreases UCH-L1 protein level and its hydrolase activity through HtrA2-mediated cleavage of UCH-L1 under apoptotic conditions. These findings suggest that the HtrA2-mediated cleavage of UCH-L1 may play important roles in regulating the fine balance between cell growth and cell death.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001920     DOI: 10.1016/j.bbrc.2011.09.148

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Protease Omi facilitates neurite outgrowth in mouse neuroblastoma N2a cells by cleaving transcription factor E2F1.

Authors:  Qi Ma; Qing-song Hu; Ran-jie Xu; Xue-chu Zhen; Guang-hui Wang
Journal:  Acta Pharmacol Sin       Date:  2015-08       Impact factor: 6.150

Review 2.  Integrating pathways of Parkinson's disease in a molecular interaction map.

Authors:  Kazuhiro A Fujita; Marek Ostaszewski; Yukiko Matsuoka; Samik Ghosh; Enrico Glaab; Christophe Trefois; Isaac Crespo; Thanneer M Perumal; Wiktor Jurkowski; Paul M A Antony; Nico Diederich; Manuel Buttini; Akihiko Kodama; Venkata P Satagopam; Serge Eifes; Antonio Del Sol; Reinhard Schneider; Hiroaki Kitano; Rudi Balling
Journal:  Mol Neurobiol       Date:  2013-07-07       Impact factor: 5.590

3.  Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi.

Authors:  Vilmos Csizmadia; Paul Hales; Christopher Tsu; Jingya Ma; Jiejin Chen; Pooja Shah; Paul Fleming; Joseph J Senn; Vivek J Kadambi; Larry Dick; Francis S Wolenski
Journal:  Toxicol Res (Camb)       Date:  2016-08-25       Impact factor: 3.524

4.  Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS.

Authors:  Shaochun Zhu; Anna Wuolikainen; Junfang Wu; Anders Öhman; Gunnar Wingsle; Thomas Moritz; Peter M Andersen; Lars Forsgren; Miles Trupp
Journal:  J Mol Neurosci       Date:  2019-11-12       Impact factor: 3.444

5.  The proteases HtrA2/Omi and UCH-L1 regulate TNF-induced necroptosis.

Authors:  Justyna Sosna; Susann Voigt; Sabine Mathieu; Dieter Kabelitz; Ahmad Trad; Ottmar Janssen; Catherine Meyer-Schwesinger; Stefan Schütze; Dieter Adam
Journal:  Cell Commun Signal       Date:  2013-10-03       Impact factor: 5.712

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.